| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.015 | 0.9 |
| mRNA | BRD-K45681478 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |